Pulmonary Function in Infants with Postviral Chronic Pulmonary Disease (PCPD)

Viral injury, perticularlly secondary to adenovirus infection, may cause severe impairment of the respiratory tract in infants. This study was designed to evaluate the pulmonary function and

bronchodulator response in infants with clinical and virologic diagnosis of PCPD. 13 patients (M=5, F=8), mean age 1.32 years with a history of PCPD were included. Control group (CTRL),

included 13 patients (M=9, F=4), mean age 1.16 years. There were no significant differences in age or height between both groups. A Sensor Medics 2600 system was used. The parameters

assessed were. Respiratory Rate (RR), Peak Tidal Expiratory Flow (PTEF), Volume (%V-PF), and Time (Tme/Te) percentages for PTEF (T-PTEF) and PTEF/Tidal Volume ratio (PTEF/TV), Compliance

(Crs) and Resistance (Rrs) of respiratory system and Maximal Flow at Functional Residual Capacity (VmaxFRC). Bronchial responsiveness to inhaled ipatropium bromide (IB) 0.02 mg/kg and

albuterol (AL) 0.25 mg/kg were evaluated in the PCPD group on different days for all functional parameters. Results(x±SD) were as follows: Table VmaxFRC was obtained at 15, 30, 45 and 60

minutes after each nebulization. No differences were found with any of the bronchodilators. Parameters from the Tidal Flow/Volume Curves and Respiratory Mechanic were obtained at 45 minutes,

and their variations were not significant. We conclude that infants with PCPD have severe obstructive and restrictive disorders that are not modified by inhaled IB or AL adminitration.

Anyone you share the following link with will be able to read this content: